In the fourth quarter of 2024, one Biologics company received an FDA inspection in Connecticut, according to the U.S. Food and Drug Administration (FDA).
This was the lowest number of inspections per type of company made by the FDA in Connecticut, equalling 8.3% of all inspections in the fourth quarter of 2024.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality.
| Project Area | No Action Indicated | Voluntary Action Indicated | Official Action Indicated |
|---|---|---|---|
| Blood and Blood Products | 1 | — | — |
| Compliance: Devices | 3 | 1 | — |
| Foodborne Biological Hazards | 5 | 1 | — |
| Human Cellular, Tissue, and Gene Therapies | 1 | — | — |
| Postmarket Assurance: Devices | 3 | — | — |
| Radiation Control and Health Safety Act | 1 | — | — |
| Technical Assistance: Food and Cosmetics | 2 | 1 | — |
